|
|
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain
,
Bert Bonsing
,
Thierry Conroy
,
Adelaide Dousseau
,
Bengt Glimelius
et al.
Article dans une revue
hal-01802621v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
Thomas T. Aparicio
,
Michel Ducreux
,
Roger Faroux
,
Emilie Barbier
,
Sylvain Manfredi
et al.
Article dans une revue
hal-01983308v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
Simon Pernot
,
Cecile Badoual
,
Magali Terme
,
Florence Castan
,
Aurelie Cazes
et al.
Article dans une revue
hal-01579145v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
David Tougeron
,
Pierre Michel
,
Astrid Lièvre
,
Michel Ducreux
,
Sébastien Gaujoux
et al.
Article dans une revue
hal-03102287v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours
Come Lepage
,
Laetitia Dahan
,
Nadia Bouarioua
,
Christos Toumpanakis
,
Jean-Louis Legoux
et al.
Article dans une revue
hal-01599909v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|